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Structure–Function Relation of Efomycines, a Family
of Small-Molecule Inhibitors of Selectin Functions
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Matthias Busemann3, W. Henning Boehncke4 and Michael P. Scho¨n1
Selectin-mediated leukocyte adhesion to endothelia, the crucial first step initiating the pathogenic cascade of
inflammation, is an attractive target for specific therapies. The small-molecule macrolide, efomycine M, inhibits
selectin-mediated leukocyte adhesion in vitro and in vivo, and effectively alleviates inflammatory disorders in
vivo. To define the molecular basis of the therapeutically relevant antiadhesive properties of efomycines, several
new species of this family were purified and/or synthesized. Efomycines E and G were isolated from
Steptomyces BS1261. Efomycine O was synthesized by Lewis acid-catalyzed acetalization and efomycine M was
generated by base-catalyzed deglycosylation. Efomycine S resulted from ester cleavage of the macrolide ring
system, and efomycine T represents the peracetylated form of efomycine M. When the functional activity of
efomycines on adhesion of leukocytes to vascular endothelium was studied, some remarkable differences
between the compounds became apparent, inasmuch as efomycines E, G, M, and O significantly inhibited
adhesion of both human and porcine leukocytes to the vascular endothelium, whereas efomycines S and T did
not show any biological activity. A novel docking engine (ProPose), generating an improved, fully configurable
protein–ligand interaction model, demonstrated that biological activities of efomycines can be predicted in
silico, thus highlighting the utility of such combinatorial approaches.
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INTRODUCTION
Tissue-specific leukocyte localization is an essential require-
ment for immune surveillance and plays a key role in the
pathogenesis of various inflammatory diseases. Recent
advances in our understanding of the molecular mechanisms
underlying the complex multistep cascade resulting in
localization of circulating leukocytes to sites of inflammation
or injury (Robert and Kupper, 1999; von Andrian and
Mackay, 2000) have greatly aided the identification of
specific therapeutic target structures and the development
of innovative anti-inflammatory compounds. Specific inter-
ference with the initial steps of leukocyte recruitment is
predicted to result in anti-inflammatory effects (Boehncke
and Scho¨n, 2003; Ulbrich et al., 2003; Scho¨n and Ludwig,
2005).
Leukocytes usually attach to post-capillary venules, where
the shear stress is lowest (Alon et al., 1998). The first steps of
tissue localization to all tissues involve transient interactions
of selectins that bind to carbohydrate ligands displayed on
glycoprotein scaffolds (Varki, 1994; Feizi, 2001; Ley, 2001).
These interactions, which are supported by the very late
activation antigen-4 (VLA-4) integrin function (Issekutz and
Issekutz, 2002), cause tethering and rolling of flowing
leukocytes on the endothelial cell surface. The slow velocity
of rolling leukocytes on selectins favors encounters with
glycosaminoglycan-bound chemokines presented on the
endothelial lining to chemokine receptors expressed by
leukocytes (Gerard and Rollins, 2001; Scho¨n and Ruzicka,
2001). Short-lived selectin–glycoprotein interactions mediate
the transition of flowing leukocytes into a rolling motion
along the endothelial cells. Selectins bind weakly to sialyl
LewisX (sLeX)-like glycans, but with high affinity to specific
glycoprotein counter-receptors. T lymphocytes are known to
bind P-selectin through P-selectin glycoprotein ligand-1
modified by appropriate glycosylation and tyrosine sulfata-
tion. Differential post-translational modification of P-selectin
glycoprotein ligand-1, mediated by fucosyltransferase VII,
results in the generation of cutaneous lymphocyte antigen, an
E-selectin ligand expressed on skin-homing T lymphocytes
(Fuhlbrigge et al., 1997; Somers et al., 2000). Thus, mole-
cules involved in selectin-mediated adhesive interactions
offer several (complementary) approaches for therapeutic
interventions.
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Efomycine M is the lead compound of a new family of
agents interfering with leukocyte–endothelial cell adhesive
interactions, a process that is mediated by selectins (Scho¨n
et al., 2002). As demonstrated previously, efomycine M has
demonstrated profound interference with selectin-mediated
leukocyte adhesion that resulted in diminished leukocyte
rolling in blood vessels in vivo as well as in alleviation of
cutaneous inflammation in two complementary mouse
models of psoriasis, one of the most common chronic
inflammatory skin disorders in humans (Scho¨n and
Boehncke, 2005).
In order to closely examine this therapeutically relevant
action and to define the molecular basis for the selectin-
directed antiadhesive properties, we have here purified and/
or synthesized several new species of the efomycine family.
Of note, relatively minor molecular modifications resulted in
profound changes of the biological activity, a finding that is
well in line with the results obtained by a novel docking
engine (ProPose) (Seifert et al., 2004), suggesting differential
interaction characteristics and binding scores of efomycine
species docked into the E-selectin ligand binding site.
RESULTS
Purification of naturally occurring efomycines and generation
of novel efomycine species
To assess the ultrastructural conformation and active struc-
tures of efomycines required for inhibition of leukocyte
adhesion, the naturally occurring components of the Strepto-
myces BS 1261 fermentation material were purified by HPLC,
and analyzed by thin-layer chromatography, reversed-phase
HPLC, proton nuclear magnetic resonance (1H-NMR) spec-
troscopy, and fast atom bombardment (FAB)-mass spectro-
metry (MS). As expected (Scho¨n et al., 2002), four naturally
occurring compounds could be isolated: efomycine A
(Mr¼1,038, 16% of the total material), efomycine B
(Mr¼1,052, 2%), efomycine E (Mr¼ 1,024, 68%), and
efomycine G (Mr¼1,010, 14%). The latter two species could
be purified in quantities sufficient for cell adhesion experi-
ments. In addition, several biochemical modifications were
synthesized for an in-depth investigation of structure–function
relations on the molecular level.
The naturally occurring efomycine species were acidic
and base-sensitive compounds, which could decompose via
aldol cleavage at C9/C10 and elimination of the L-desoxyfu-
cose side chain. This destruction could be avoided by Lewis
acid-catalyzed acetalization in methanol forming the di-
O-methylated species, efomycine O. FAB-MS revealed
Mr¼1,052 for efomycine O. Efomycine M (Mr¼728)
represents the di-defucosylated form of the naturally occur-
ring efomycine E, which was synthesized by base-catalyzed
b-elimination of the desoxyfucose side chain (Scho¨n et al.,
2002). The symmetrical molecule, efomycine M, was then
used as the substrate for macrolide cleavage. Under mild
basic conditions, the O-bonds of this ring system were
cleaved, resulting in a linear fragmentation product
of Mr¼ 377, now termed efomycine S. Finally, reaction
of efomycine M with pyridine/acetic anhydride resulted in
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Figure 1. Structures of efomycine species. Efomycines E and G are the naturally occurring species isolated from fermentation material of Streptomyces BS1261.
As outlined in Materials and Methods, efomycine O was synthesized by di-O-methylation; efomycine M is the de-fucosylation product, efomycine S results from
macrolide cleavage of efomycine M, and efomycine T is the tetra-O-acetylated form of efomycine M.
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FAB-MS, the molecular weight of efomycine T was Mr¼919,
corresponding to tetra-O-acetylated efomycine M. Structures
of the novel efomycines are depicted in Figure 1.
Differential effects of efomycines on leukocyte–endothelial cell
adhesion
To approach the question whether efomycines might interfere
with leukocyte adhesion to endothelial cells in an experi-
mental setting approximating the in vivo situation, we
performed adhesion experiments using porcine or human
polymorphonuclear leukocytes and hypoxia-stimulated por-
cine aortas. When human leukocytes were studied, efomy-
cines E, G, M, and O showed significant inhibitory capacities
at concentrations of 105 M, with efomycine G inhibiting
adhesion by 65.2%, efomycine M inhibiting adhesion by
74.5% (Po0.001 as compared to control cultures in both
cases), efomycine E inhibiting adhesion by 47.3% (Po0.01),
and efomycine O inhibiting adhesion by 41.3% (Figure 2a).
Interestingly, efomycines S and T did not inhibit adhesion of
human leukocytes to the aortic endothelium (Figure 2a). Of
note, when adhesion of porcine leukocytes to the aortic
endothelium was assessed, a similar pattern of activities
became apparent: the inhibitory effects of efomycines E and
M were similar to those seen with human leukocytes and
were 52.1 and 67.7%, respectively (Po0.001 in both cases).
Efomycine O (inhibition by 68.9%, Po0.001) and efomycine
G (inhibition by 45.6%, Po0.01) also showed significant
binding inhibition of porcine leukocytes (Figure 2b). Again,
efomycines S and T did not inhibit adhesion of porcine
leukocytes to the aortic endothelium. To rule out the possi-
bility that different activities of efomycines were owing to
varying solubilities in the aequeous media, the concentrations
of efomycines in the assay buffer were monitored fluoro-
metrically. No significant alterations in UV absorption were
observed during the 90 minutes observation period (data not
shown).
Thus, the desoxy-fucose moiety, which is deleted in
efomycine M, did not appear to play a critical role for specific
antiadhesive properties in leukocyte–endothelial cell adhesion.
The presence of carbohydrate side chains, as displayed in
efomycine E, appeared to diminish the inhibitory activity of the
molecule. Introducing acetyl groups, as shown with efomycine
T, completely abolished the inhibitory activity. Likewise, ester
cleavage of the macrolide ring system, as demonstrated with
efomycine S, abrogated the adhesion-blocking capacity of the
molecule. The results obtained in leukocyte/endothelial cell
adhesion assays were supported by preliminary data demon-
strating similar differential effects of efomycine species on
leukocyte–platelet adhesion (data not shown).
Docking of efomycines to the ligand-binding domain
of E-selectin
Intrigued by the differential biological activities of chemically
related compounds of the efomycine family towards leuko-
cyte/endothelial cell binding, we sought to gain insight
into the molecular basis underlying the binding of
efomycines to selectins. Structural analyses based on the
identification of pharmacophoric groups as described earlier
(Scho¨n et al., 2002) were not sufficient to explain the
molecular basis of the rather surprising differences in the
biological activities of efomycine species. Thus, in order to
overcome this limitation and to approach binding sites and
binding affinities, we employed the novel docking engine,


























































































Figure 2. Biological activities of efomycines on leukocyte/endothelial adhesion. (a) Human or (b) porcine polymorphonuclear leukocytes were allowed to
adhere to hypoxia-stimulated endothelium of ex vivo porcine aortas for 90 minutes in the presence of 105 M of the different efomycines as indicated. Adhesion
was measured by determination of the activity of the neutrophil-specific enzyme, myeloperoxidase. The values shown represent averages of three independent
adhesion assays (7s.d.). **P-values o0.01; ***P-values o0.001 as compared to the untreated control; NS¼ nonsignificant.
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configurable protein–ligand interaction model to analyze
members of the efomycine family regarding their interaction
with the ligand-binding domain of E-selectin (the only
published selectin crystal structure; Somers et al., 2000).
Efomycine M, showing strong selectin-directed binding
inhibition, efomycine E, showing moderate activity, and the
biologically inactive forms, efomycines S and T, were





Figure 3. Docking of efomycines into the crystal structure of E-selectin. (a) The docking complex of E-selectin (protein backbone shown as blue tube) with sLeX
(yellow structure) was generated using the ProPose engine on the basis of Protein Data Bank entry 1G1T as outlined in Materials and Methods. (b) Active
receptor surfaces within this complex are highlighted (light green surface) to demonstrate the location of sLeX within the ligand-binding groove. (c) Docking
result of Efomycine M (red) into the active site of E-selectin as compared to that of sLeX (yellow) to demonstrate the differential orientation within the ligand-
binding groove and the different amino-acid residues mediating binding of the two structures. The location of the Ca2þ ion is indicated by a light blue sphere.
(d–f) Docking results of efomycines E (orange structure), T (light blue), and S (magenta), respectively, into the active site of E-selectin. Efomycine M (red) and sLeX
(yellow) are depicted in each panel for comparison. (g) The summary of the docking results of all of the efomycines tested into the ligand binding site of
E-selectin.
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In the initial series of analyses, the natural selectin ligand,
sLeX, was docked into the rather flat ligand-binding groove of
E-selectin (Figure 3a and b). As the docking procedure
demonstrated that sLeX was an overall weak binder (ProPose
score 11.4; low values indicate strong binding as the scores
correlate with the free binding enthalpy, DGbind; ProPose
scores provide a ranking of the ligands (Seifert et al., 2004)),
this initial analysis convincingly confirmed known properties
of sLeX and corroborated the validity of the procedure for
analyses of E-selectin–ligand interactions. The natural selectin
ligand, sLeX, mainly forms seven H-bonds to the active site of
E-selectin: six hydroxyl groups of the Fuc, the Gal, and the
NeuNAc moieties interact with the Ca2þ ion and the Glu 92,
Tyr 94, Tyr 48, and Arg 97 residues of E-selectin. In addition,
Arg 97 builds a salt bridge to the carboxylate group of the
NeuNAc moiety (Figure 3c).
In the next series of experiments, it was found that all
efomycine species could be docked into the active site of
E-selectin (Figure 3c–g). Interestingly, the ProPose scores of
the crystallographic placement of sLeX and the docking poses
of the efomycine derivatives were largely predictive of the
results from our biological analyses: Efomycine M had the
lowest score (39.2) and thus the best predicted biological
activity. The scores of efomycines E, T, and S (21.8, 20.7,
and 15.6, respectively) predicted weaker binding. Within
the docking solution of efomycine M (Figure 3c), one part of
the molecule showed, similar to sLeX, interactions with the
region around the divalent Ca2þ ion, whereas the remaining
part of the efomycine M molecule was placed apart from the
sLeX binding groups. Efomycine M formed H-bonds with its
oxygen atoms in the ring and both of the respective hydroxyl
groups located nearest to the ring. Interacting amino acids of
E-selectin were Asn 82, Asn 83, Tyr 94, Arg 97, and Asp 100.
Thus, the orientation of efomycine M within the E-selectin
binding pocket showed some remarkable differences as
compared to that seen with sLeX (Figure 3c).
As the central ring systems of efomycines E and M have
nearly identical placements, efomycine E showed a similar
binding mode as compared to efomycine M (Figure 3d).
However, owing to the voluminous sugar moieties present at
both sides of efomycine E (Figure 1), it appeared to be
sterically impossible for this ligand to form H-bonds with its
hydroxyl groups nearest the central ring, as efomycine M
does.
Efomycine T exhibited a completely different binding
mode as compared to efomycine M (Figure 3e). Owing to its
acylated hydroxyl groups (Figure 1), efomycine T is devoid of
any H-donors and adopts a rather globular conformation.
This is the reason for its low activity.
In contrast, efomycine S exhibited a good balance of H
donors and acceptors. It also binds in the region around the
Ca2þ ion (Figure 3f). However, the reasons for its low
docking score and the corresponding low biological activity
are the only half as many possible interaction sites as
compared to efomycine M and its much higher flexibility
caused by the lack of the central ring system (Figure 1). The
positioning of all of the efomycine species is summarized in
Figure 3g.
DISCUSSION
Overall, we have demonstrated that it is possible to generate
novel members of the efomycine family, which show
differential biological activities towards selectin-mediated
leukocyte/endothelial cell adhesive interactions. In addition,
we have demonstrated that the novel docking engine,
ProPose, can be employed successfully to predict in silico
the biological activities of several members of this family
based on their docking scores to the E-selectin ligand binding
site. The biological and chemical approach to study activities
of new compounds, on the one hand, and computational
modeling of receptor–ligand interactions, on the other hand,
were thus successfully merged, exemplarily using a novel
family of compounds. Our results suggest that this principle
may be utilized for other compounds intended to target
selectin functions or, possibly, other receptor molecules.
Computational approaches that dock small molecules into
the binding pockets of target proteins and score their
complementarity to binding sites are increasingly used in
compound identification and lead optimization (Bajorath,
2002; Bleicher et al., 2003). Modern computational ap-
proaches appear to be valuable additions to the currently
available armamentarium for rational drug design, and they
will undoubtedly contribute to a more rapid and less cost-
intensive identification of potential lead compounds as
compared to more traditional techniques of compound
library screening, chemical modification, and crystal struc-
ture analysis applied to the development of specific small
molecule inhibitors of selectins and other target molecules
(Kaila and Thomas, 2002). Computational approaches may
not, however, replace those traditional techniques, which are
needed to test the hits generated in silico.
It has been proposed recently that the activity of some
quinic acid derivatives as selectin inhibitors is based on the
formation of complexes with the functionally relevant Ca2þ
ion within the ligand binding site (Kaila et al., 2005). As the
ProPose engine employed in our study also predicted
interactions of biologically active efomycines with the central
Ca2þ ion, it is conceivable that such interactions may be a
common mode of action of several selectin inhibitors.
There was an apparent discrepancy between the biologi-
cal activity of efomycine E (showing moderate but significant
inhibition of leukocyte binding) and its rather high docking
score of 21.8, which was close to that calculated for the
biologically inactive efomycine T (20.7). At least one
plausible explanation for this observation can be delineated:
As compared to efomycine T, efomycine E has a very high
degree of flexibility (i.e., the number of nearly free rotatable
cyclic and acyclic single bonds is twice as large as that of
efomycine T). This might lead to a suboptimal placement of
this particular ligand by the docking algorithm. Therefore, the
optimal solution, which would show a more negative score
for efomycine E, was probably not found by the docking
algorithm. It is, therefore, likely that the rather small
calculated difference between the docking score of efo-
mycine E and that of efomycine T can be attributed to the
above-mentioned inherent feature of the docking algorithm.
As this issue applies only to efomycine E, but not to the other
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efomycine species tested, the predicted docking score of
efomycine E can be regarded as too high.
Efomycines interfering with leukocyte binding to endothe-
lial cells presumably diminish crucial events in the multistep
process of leukocyte localization to sites of inflammation,
thus interrupting the inflammatory cascade at its earliest steps
(Springer, 1994; Butcher and Picker, 1996; Boehncke and
Scho¨n, 2003; Scho¨n et al., 2003). This mechanism may be of
great utility for a variety of major illnesses including common
immunologically mediated inflammatory disorders, such as
psoriasis (Scho¨n and Boehncke, 2005), inflammatory bowel
diseases (Salmi and Jalkanen, 1998), or rheumatoid arthritis
(Sfikakis and Mavrikakis, 1999). Other examples highlighting
pivotal pathogenic roles of selectin-mediated adhesion
comprise tumor metastasis (Ludwig et al., 2004), thrombus
formation, and atherosclerosis (Falke et al., 2000). In
addition, selectin-mediated leukocyte localization and leu-
kocyte/platelet interactions are thought to be key events in
reperfusion injury (Barros et al., 2000). Thus, it is conceivable
that antiadhesive principles, such as those elicited by
efomycines, may be useful in a variety of pathophysiological
settings.
MATERIALS AND METHODS
Isolation and purification of the naturally occurring efomycines
E and G
As described recently (Scho¨n et al., 2002), fermentation material of
Streptomyces BS 1261 was the source for the isolation of efomycines
E and G. Briefly, the crude mixture was separated by reversed-phase
HPLC, and the compounds were detected by UV adsorption at
250 nm. The peaks were detected after elution times ranging from
10.0 to 23.2 minutes, collected and analyzed by thin-layer
chromatography (TLC, RP18-plate; Merck, Darmstadt, Germany;
acetonitrile:water¼ 9:1) and FAB-MS chromatography. The sub-
stances were then further characterized by thin-layer chromatogra-
phy, analytical reversed-phase chromatography on an RP18-HPLC
column (Merck), 1H-NMR spectroscopy, and FAB-MS. Finally,
efomycines G and E were purified by HPLC in quantities sufficient
for cell adhesion assays and further chemical modifications.
Synthesis of efomycine O
The di-O-methylated form, efomycine O, was synthesized from the
Streptomyces BS 1261-derived efomycine mixture by Lewis acid-
catalyzed acetalization in methanol as described (Hamann and
Kretzschmar, 1990) with minor modifications. Briefly, 1 g of the
above efomycine mixture was stirred for 5 minutes with 10 mg FeCl3
in 10 ml methanol. The reaction products were then concentrated by
desiccation, and analyzed by thin-layer chromatography (RP18-
plate, Merck). In addition to the non-reacted compounds, two new
species could be detected that revealed lower polarity as compared
to the original compounds (Rf of 0.36 and 0.24, respectively). The
new compounds were further purified by silica gel chromatography
using 8% methanol in dichlormethane (CH2Cl2) as solvent, and
analyzed by FAB-MS and 1H-NMR spectroscopy. It was found that
the new species, now termed efomycines N and O, respectively
(Mr¼ 1,038 and 1,051, respectively), represented the mono-
O-methylated (substituted at carbonyl group 11) and the di-O-
methylated (substituted at carbonyl groups 11 and 110) efomycine
E. Efomycine O could be purified in quantities sufficient for
biological assays.
Synthesis of efomycine M
In order to synthesize the defucosylated species, efomycine M, we
performed a base-catalyzed deglycosylation leading to b-elimination
of the deoxyfucose side chains as described (Hamann et al., 1990;
Scho¨n et al., 2002). Briefly, 1 g of the Steptomyces BS 1261-derived
efomycine mixture was refluxed in a mixture of 15 ml H2O, 5 ml
ethanol, 7 ml ethyl-acetate, and 2.5 g KHCO3 (all chemicals were
from Merck) for 6 hours. The organic phase was then evaporated and
the residue extracted with ethyl-acetate. The resulting mixture was
then subjected to silica gel chromatography (solvent
chloroform:methanol¼ 8:1) and further analyzed by FAB-MS and
1H-NMR spectroscopy. As expected (Scho¨n et al., 2002), the species
detected with Mr¼ 876 represented the di-defucosylated efomycine M.
Synthesis of efomycine S
In the next series of experiments, efomycine M was cleaved under
mild basic conditions at the ester linkage of the macrolide ring,
resulting in efomycine S. Briefly, 5 mg efomycine M were allowed to
react overnight at room temperature with 500 ml of 50 mM
methanolic sodium hydroxide. After neutralization with 1 M HCl
and evaporation of the volatile solvent, the residue was diluted in
2 ml H2O, and the hydrophobic product was extracted three times
with 0.5 ml dichlormethane (CH2Cl2), washed twice with 1 ml H2O,
and the solvent evaporated again. The resulting product was then
purified by silica gel chromatography (silica gel 60, Merck; solvent
dichloromethane:methanol¼ 16:1) and thin-layer chromatography
(RP18-plates, Merck; eluent methanol:water¼ 9:1). The major
product was then identified by FAB-MS and 1H-NMR spectroscopy
as the macrolide-cleaved species, termed efomycine S (Mr¼ 377).
Synthesis of efomycine T
To synthesize the peracetylated species, efomycine T and 2 mg
efomycine M were diluted in 300 ml of a 1:1 mixture of pyridine/
acetic anhydride and allowed to react at room temperature
overnight. Following evaporation, the resulting products were again
analyzed by FAB-MS and 1H-NMR spectroscopy. The new com-
pound represented the tetra-O-acetylated derivative of efomycine
M, now termed efomycine T (Mr¼ 919).
1H-NMR spectroscopy
The solution structures and three-dimensional conformations were
assessed for efomycines E, G, M, O, S, and T. All NMR spectra were
recorded at 500 MHz on a Bruker AMX-500. Typical concentrations
of the compounds were 1–5 mg/0.6 ml DMSO-d6. The proton
assignment was based upon phase-sensitive Double Quantum-
Filtered Correlation Spectroscopy and Total Correlated Spectroscopy
experiments. Coupling constants were derived from one-dimen-
sional proton spectra, and distance constraints were obtained from a
single Nuclear Overhauser Effect Spectroscopy spectrum with a
mixing time of 350 ms. The integrated intensities of the cross-peaks
resulted from volume integration. To assign the proton resonances,
two-dimensional Correlation Spectroscopy experiments (in which
cross-peaks between directly coupled protons were observed) and
Total Correlated Spectroscopy experiments (yielding additional
cross-peaks between protons within one spin system that are several
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bonds apart) were combined. Substantial overlap was observed for
many CHOH protons at 3.8 p.p.m. The resonances of all OH protons
were sharp, indicating a small exchange rate with residual water in
the sample.
In order to determine the conformation of efomycines in solution,
two-dimensional Nuclear Overhauser Effect Spectroscopy experi-
ments were performed yielding cross-peaks between two protons
whenever they were in close vicinity. The integrated intensities of
these cross-peaks correlated with the interproton distance: IijBrij
6.
As the intensities drop rapidly with increasing distances, Nuclear
Overhauser Effects can only be detected for distances shorter than
3.5–4 A˚.
Leukocyte adhesion to ex vivo aortic endothelium
Freshly excised porcine aortas were transported in oxygenated
phosphate-buffered saline from a local slaughterhouse into the
laboratory. Freshly collected heparinized porcine or human blood
was used for the preparation of neutrophilic granulocytes by density-
gradient centrifugation. The aortic endothelial cells were stimulated
and induced to express selectins by placing them for 30 minutes into
phosphate-buffered saline gassed with N2. Thereafter, they were
fixed between a Teflon block and a specially designed stainless-steel
plate with drilled holes. Neutrophils and the different efomycines (at
concentrations of 105 and 104 M, respectively) were added to the
medium (M199; GibcoBRL, Karlsruhe, Germany) onto the luminal
side with the stimulated endothelial lining. After 90 minutes
incubation at 371C, the wells were washed, adherent cells were
lyzed, and the activity of the neutrophil-specific enzyme, myeloper-
oxidase, was assessed photometrically according to the manufac-
turer’s instructions (Sigma, Deisenhofen, Germany). Test compounds
and controls were generally analyzed on the same aorta; all
experiments were run in triplicate.
Statistical significance was assessed by the paired two-tailed t-
test, and Po0.05 was considered statistically significant.
Docking analyses of efomycines to E-selectin
In order to get a hold on the differential biological activities of the
efomycine derivatives towards selectin-mediated adhesion, we set up
docking analyses using the crystal structure of the Protein Data Bank
(Berman et al., 2000) entry 1G1T, a co-complex of human E-selectin
and sLeX (Somers et al., 2000). Only the structural data of the protein
and the Ca2þ ion of 1G1T was used to set up the ProPose docking
procedures (Seifert et al., 2004). The modeling tool MOLOC (Gerber,
1998) was used to add all hydrogen atoms in energy-minimized
positions. In order to save computing time, we defined an active site
on the protein surface by a 12 A˚ distance criterion to the substrate
molecule sLeX. Further investigations showed that including the whole
protein surface into the docking procedure generated the same poses
of the docked molecules. This approved the definition of the active
site as the region around the co-crystallized sLeX.
The input structures of the ligand molecules were generated
with the modeling software MOE. Given that structure generation
of ring systems with more than eight ring atoms is not possible
with ProPose, we performed conformational search runs with MOE
for efomycines M, T, and E. This resulted in approximately 20
different ring conformations for each of the cyclic efomycine
derivatives. All of these conformations were used for the final
docking calculations.
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